HER2-targeted antibody–drug conjugate linking trastuzumab to the maytansinoid DM1 via a non-cleavable linker; inhibits HER2 signaling, mediates ADCC, and delivers DM1 to disrupt microtubules, causing mitotic arrest and apoptosis.
HER2-targeted antibody–drug conjugate: the trastuzumab antibody binds HER2, inhibits HER2 signaling and mediates ADCC, is internalized, and via a non-cleavable linker delivers the microtubule inhibitor DM1, which binds tubulin to disrupt microtubule dynamics, causing mitotic arrest and apoptosis in HER2-overexpressing tumor cells.
NO
INDIRECT
The ADC targets HER2, not beta-tubulin; only HER2-positive cells internalize the drug and receive DM1, which then binds tubulin to disrupt microtubules and cause cell death. Cells expressing beta-tubulin alone are not targeted or directly killed.
Antibody–drug conjugate targeting TROP2; upon binding and internalization, releases a topoisomerase I inhibitor payload that induces DNA damage and tumor cell death, with potential bystander effect.
Humanized anti-TROP2 IgG1 ADC that binds TROP2 on tumor cells and is internalized; pH/enzymatic cleavage of the linker releases the topoisomerase I inhibitor tirumotecan, inhibiting Topo I, inducing DNA damage, replication arrest, and apoptosis, with a membrane-permeable payload enabling a bystander effect.
YES
DIRECT
ADC binds TROP2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor that induces DNA damage, replication arrest, and apoptosis; membrane-permeable payload can also cause a bystander effect.
Antibody–drug conjugate targeting TROP2; upon binding and internalization, releases a topoisomerase I inhibitor payload that induces DNA damage and tumor cell death, with potential bystander effect.
Humanized anti-TROP2 IgG1 ADC that binds TROP2 on tumor cells and is internalized; pH/enzymatic cleavage of the linker releases the topoisomerase I inhibitor tirumotecan, inhibiting Topo I, inducing DNA damage, replication arrest, and apoptosis, with a membrane-permeable payload enabling a bystander effect.
NO
INDIRECT
SKB264 targets TROP2, is internalized, and releases the Topo I inhibitor tirumotecan, which inhibits DNA topoisomerase I to cause DNA damage and apoptosis (with a bystander effect); Topo I expression itself is not what the ADC binds or selects.
IV chimeric anti-CD20 monoclonal antibody that depletes B cells via complement- and antibody-dependent cytotoxicity and apoptosis, reducing humoral immune activity and stabilizing podocyte injury.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby suppressing humoral immune activity and stabilizing podocyte injury.
YES
DIRECT
Rituximab binds CD20 on B cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC, and can induce apoptosis, directly killing CD20+ cells.
Anti-CD20 monoclonal antibody that depletes B cells; used for EBV-PTLD prophylaxis and immune modulation.
Chimeric anti‑CD20 monoclonal antibody that binds CD20 on pre‑B and mature B cells and induces B‑cell depletion via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and apoptosis; used to reduce B cells for EBV‑PTLD prophylaxis and immune modulation.
YES
DIRECT
Anti-CD20 antibody binds CD20 on B cells and kills via Fc-mediated ADCC (NK cells/macrophages) and complement-dependent cytotoxicity; it can also induce apoptosis of CD20+ cells.